Products

Medical device maker Stryker Corp said on Tuesday that it is a target of a federal grand jury probe related to the illegal promotion of human bone growth products and other issues.

SyntheMed, Inc., a biomaterials company engaged in the development and commercialization of anti-adhesion products, today announced that the U.S. Food and Drug Administration has approved the Pre-market Approval application for REPEL-CV® Adhesion Barrier for use in pediatric cardiac surgery patients.

Rush University Medical Center scientists in Chicago say they have identified an immunological reaction that leads to early failure of joint implants.

Angiotech Pharmaceuticals, Inc. today announced positive clinical study results for its Bio-Seal™ Lung Biopsy Tract Plug System at the
Society of Interventional Radiologists Annual Scientific Meeting in San Diego, CA.

AOI has pioneered a better way to treat VCF. The company’s lead product, Ascendx™, is used to restore height by pushing on the bone walls while simultaneously delivering a medical grade bone cement, uniformly filling the cavity, thereby restoring height and allowing equal forceload distribution to the vertebra.

Spine surgeons at Middlesex Hospital in Middlesex Connecticut have performed a minimally invasive, posterior spinal fixation procedure using the Lock-Tight™ Facet System, a groundbreaking new technology that enables surgeons to fixate the facet joint without needing to perform an open procedure.

Bayer Schering Pharma welcome NICE’s Final Appraisal Determination giving a draft recommendation that Xarelto (rivaroxaban), within its marketing authorisation, is recommended as an option for the prevention of venous thromboembolism in adults having elective total hip or elective total knee replacement surgery.

The Hip and Knee Network has just published its 2009 survey of hip and knee replacement surgery in the UK.

Increasing numbers of patients in North America are receiving hip and pelvis surgery that protects tissue, offers faster recovery, allows for more accurate placement of medical implants and reduces post-operation restrictions compared to traditional hip surgery.

Angiotech Pharmaceuticals, Inc. today announced its financial results for the fourth quarter and year ended December 31, 2008.

Abiomed, Inc., a leading provider of heart recovery products designed to recover hearts and eliminate in-hospital deaths from heart attacks and high risk percutaneous coronary interventions, announced today the appointment of Michael Howley as Vice President and General Manager, Global Sales and Marketing.

TYRX, Inc., a leader in the commercialization of implantable medical-pharmaceutical devices, today announced that it has appointed Gail O’Brien Turner as Vice President, Sales.

Information Portal Consumer Injury Lawyers continues to update its Zimmer Durom Hip Replacement Part information portal with new articles providing more detail and insight relating to Zimmer Hip Implant Lawsuits.

Small Bone Innovations, Inc. (SBi) announced today that an ‘Approvable Letter’ has been received from the U.S. Food and Drug Administration (FDA) for the Scandinavian Total Ankle Replacement system (S.T.A.R. Ankle).

In the first quarter, Coloplast achieved an organic growth rate of 6% and an operating profit margin of 15%. If exchange rates had not been unfavourable to Coloplast, the operating profit margin would have been 17% against 16% for the same period last year.

Flexible Stenting Solutions, Inc., a leading developer of next-generation flexible stents, announced today it has received CE Mark for its FlexStent™ Biliary Self Expanding Stent System.